Shield Therapeutics’ Feraccru yields positive results in extended phase 3 trial

Image: Feraccru was shown to increase and maintain Haemoglobin levels in the AEGIS-CKD study. Photo: courtesy of cuteimage/FreeDigitalPhotos.net.